In this post hoc analysis we investigated the effects of insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus comparators on cardiovascular (CV) risk markers in participants in the DUAL II (vs. insulin degludec), DUAL V (vs. insulin glargine 100 units/mL) and DUAL VII (vs. basal-bolus therapy) trials, grouped by sex, age (<65 years, ≥65 years) and diabetes duration (<10 years, ≥10 years). Treatment contrasts were in favour of IDegLira in many subgroups for changes from baseline in glycated haemoblogin (DUAL II, DUAL V), body weight (all three trials), systolic blood pressure (BP; all three trials), HDL cholesterol (DUAL VII) and LDL cholesterol (DUAL II, DUAL V). Higher heart rates were seen with IDegLira versus comparators (all three trials) plus significantly higher diastolic BP in men (DUAL V). Differences in treatment effect were seen between sexes in waist circumference (DUAL II), systolic BP (DUAL II, DUAL V) and triglycerides (DUAL VII), and between diabetes durations in LDL cholesterol (DUAL V). In conclusion, IDegLira is associated with a general improvement in CV risk markers compared with basal insulin or basal-bolus therapy after 26 weeks of treatment.
| INTRODUCTION
In 2008, the US Food and Drug Administration (FDA) issued guidelines stating that any new antidiabetic therapies should not result in an unacceptable increase in cardiovascular (CV) risk. 1 This was mirrored by the 2012 European Medicines Agency (EMA) diabetes guidelines, which state that new antidiabetic therapies should have either beneficial or neutral effects on variables associated with CV risk. 2 Although specific considerations for combination therapies are not provided in the FDA guidance, 1 the EMA has published a separate guidance document for fixed-combination therapies. 3 No details, however, are provided on specific CV data that need to be assessed.
While no CV outcome trials (CVOTs) have been conducted using insulin degludec/liraglutide fixed-ratio combination (IDegLira), such trials have been conducted on its monocomponents. 4, 5 To evaluate the CV effect of IDegLira, we report the analysis of CV risk markers, split by baseline characteristics, using data collected in three DUAL clinical trials. 
| Statistical analyses
All statistical analyses were performed on the full analysis set (all randomized participants) as per their respective original trials. Full statistical analysis details can be found in the Supporting Information.
3 | RESULTS
| Participants
Participants' baseline characteristics were generally well matched between treatment arms across subgroups in the three trials (Table S2 in the Supporting Information). Across the subgroups, end-of-trial insulin doses were similar between IDegLira and degludec, but lower for IDegLira compared with insulin glargine 100 units/mL (IGlar U100) or basal-bolus therapy.
| Endpoints
End-of-trial values can be found in Table S3 in the Supporting Information. Results were generally consistent with those from the overall populations. [6] [7] [8] In DUAL II and DUAL V, there were statistically significant greater reductions in HbA1c with IDegLira compared with basal insulin comparators across all baseline characteristics ( Figure 1A ,B). In DUAL VII, there were no statistically significant differences between IDegLira and basal-bolus therapy in changes in HbA1c for any baseline characteristic subgroup ( Figure 1C ). In the subgroups, the only statistically significant difference in diastolic BP was a lower BP with IDegLira compared with degludec in women in DUAL II ( Figure 1A ) and a higher BP with IDegLira compared with IGlar U100 in men in DUAL V ( Figure 1B) .
In all trials, there were statistically significant increases in heart rate with IDegLira compared with comparators, irrespective of sex, age or diabetes duration, except for participants aged ≥65 years and those with diabetes duration <10 years in DUAL VII (Figure 1 ).
Levels of LDL cholesterol were consistently lower or equal with
IDegLira compared with comparators across subgroups in all trials, with statistical significance achieved in men, participants aged <65 years and both diabetes duration subgroups in DUAL II ( Figure 2A ) and in all subgroups except in participants with diabetes duration ≥10 years in DUAL V ( Figure 2B ). In DUAL VII none of the differences were statistically significant ( Figure 2C ). There was a statistically significant different treatment effect between the diabetes duration subgroups in DUAL V (P = 0.0323 for test for treatment interaction), with a larger treatment effect seen in participants with diabetes duration <10 years.
After 26 weeks of treatment, non-HDL cholesterol levels (geometric means) were consistently lower or equal with IDegLira compared with comparators across the subgroups in all studies. A statistically significant difference in favour of IDegLira was found in all FIGURE 1 Changes in HbA1c, body weight, waist circumference and vital signs in A, DUAL II (vs insulin degludec), B, DUAL V (vs IGlar U100) and C, DUAL VII (vs basal-bolus insulin), grouped by sex, age and duration of diabetes. *P < 0.05; **P < 0.001. All analyses were based on the full analysis set. In DUAL II and DUAL V the endpoint was analysed using analysis of covariance, with treatment, pre-trial diabetes treatment (DUAL II only), region, subgroup and interaction between treatment and subgroup as fixed effects and baseline response as covariate. Missing data are imputed using last observation carried forward. In DUAL VII the endpoint was analysed using a mixed model for repeated measures including subgroup, visit, treatment, region and interaction between treatment, and subgroup as fixed factors, and baseline response as covariate.
Interactions between visit and all factors and covariates were also included. Analysis of covariance; BP, blood pressure; HbA1c, glycated haemoglobin; IDegLira, insulin degludec/liraglutide fixed-ratio combination; IGlar U100, insulin glargine 100 units/mL 
| DISCUSSION
The present analysis, overall, showed that IDegLira was associated with a generally consistent improvement in CV risk markers compared with basal insulin or basal-bolus therapy after 26 weeks of treatment across the subgroups. Treatment effect differences were seen between female and male participants in a few CV markers across the three trials, which could warrant further investigation in larger-scale and dedicated trials.
In the placebo-controlled LEADER trial, there were greater reductions in HbA1c, body weight and systolic BP with liraglutide. 4 While diastolic BP was reduced with both treatments, but more so with placebo, heart rate was higher with liraglutide compared with placebo, both in addition to standard of care. 4 In the DEVOTE trial, there was no mean difference seen between degludec and IGlar U100 in terms of body weight, BP or levels of HDL cholesterol, LDL cholesterol, total cholesterol and triglycerides. 5 In this analysis, differences were seen between IDegLira and IGlar U100 in body weight, systolic BP and LDL cholesterol, suggesting that these improvements are likely to be as a result of the liraglutide component of IDegLira; however, the dose of liraglutide administered as part of IDegLira, ranging from an average of 1.4 to 1.7 mg across the subgroups at the end of trial (Table S3 in the Supporting Information), was lower than the dose in LEADER. 4 This could imply that the beneficial effect of liraglutide on CV risk may be observed at doses lower than 1.8 mg. Liraglutide is known to result in decreases in intestinal and systemic inflammation and formation of atherosclerotic plaques. 9 As a glucagon-like peptide-1 receptor-agonist (GLP-1RA), liraglutide also acts directly on the atrium of the heart and some blood vessels. 9 It has also been postulated that increases in heart rate seen with liraglutide might be attributable to its direct effect on sympathovagal balance. ; however, SUSTAIN-6 showed a significantly lower rate of MACE with once-weekly semaglutide compared with placebo, confirming the non-inferiority of semaglutide in patients at high risk of CV events; albiglutide has been shown to be superior to placebo with respect to MACE, and dulaglutide has been shown to reduce CV risk markers such as systolic BP compared with placebo. [13] [14] [15] To our knowledge, the present study is the only study to assess CV risk in a basal insulin/GLP-1RA fixed-ratio combination. The beneficial effects of IDegLira on CV risk factors are consistent with the results from LEADER. 4 The precise mechanism by which liraglutide reduces CV risk, and whether this effect is preserved in IDegLira, remains to be determined.
Interpretation of these results is limited by their post hoc nature and lack of adjustment for multiplicity. Nevertheless, the data originate from randomized controlled trials with large cohorts and large numbers of participants in most categories. We acknowledge that endpoints such as BP were measured during study visits, which may not have represented the true 24-hour BP value. 13 Other limitations include the fact that the trials were not powered to detect treatment differences in subgroups and we were unable to determine whether the improvements seen in the various CV risk factors were secondary to improved glycaemic control or weight loss. In addition, we were unable to examine background antihypertensive and lipid-lowering therapies across populations and thus were unable to determine if these had any impact on the results. Finally, these data are surrogate risk markers with no MACE evidence from a dedicated CVOT.
FIGURE 2 Lipids in A, DUAL II (vs insulin degludec), B, DUAL V (vs IGlar U100) and C, DUAL VII (vs basal-bolus insulin), grouped by sex, age and duration of diabetes. *P < 0.05; **P < 0.001. All analyses were based on the full analysis set. In DUAL II and DUAL V the log-transformed endpoint was analysed using analysis of covariance, with treatment, pre-trial diabetes treatment (DUAL II only), region, subgroup and interaction between treatment and subgroup as fixed effects and log-transformed baseline response as covariate. Missing data were imputed using last observation carried forward. In DUAL VII the log-transformed endpoint was analysed using a mixed model for repeated measures including subgroup, visit, treatment, region and interaction between treatment, and subgroup as fixed factors, and log-transformed baseline response as covariate. Interactions between visit and all factors and covariates were also included. HDL-C, HDL cholesterol; IGlar U100, insulin glargine 100 units/mL; IDegLira, insulin degludec/liraglutide fixed-ratio combination; IGlar U100, insulin glargine 100 units/mL; LDL-C, LDL cholesterol
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